相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
1
33.3%
招募中
2
66.7%
暂无批准数据
- The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a compound annual growth rate (CAGR) of 8.0%. - The consumables segment held the largest market share at 72.5% in 2025, while pregnancy and fertility tests led test types with a 42.8% share. - North America remains the largest regional market, with Asia Pacific expected to register the fastest growth during the forecast period. - Growth is driven by rising prevalence of urinary tract infections, diabetes, and kidney and liver diseases, alongside increasing adoption of automated and point-of-care testing.
- The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, at a CAGR of 6.9%. - Consumables dominated the market with a 70.4% share in 2025, while immunoassay technology is expected to register the highest growth rate during the forecast period. - Cerebrospinal fluid analysis led the market by fluid type at 29.1% share in 2025, driven by expanding neurological disease evaluation and biomarker-based testing. - North America held the largest regional market share in 2025, while Asia Pacific is expected to be the fastest-growing region through 2031.
- Sysmex America received FDA clearance for the CN-6000™ Automated Blood Coagulation Analyzer, enabling high-throughput hemostasis testing for bleeding and clotting disorders. - The clearance includes five commonly performed hemostasis tests with specific reagent products, including PT/INR, APTT, fibrinogen, antithrombin, and D-dimer assays. - The analyzer offers fully automated testing in a space-saving footprint with expandable capacity to match different laboratory needs and workloads. - Sysmex continues pursuing market authorization for the CN-3000 analyzer and additional reagent applications to expand their hemostasis testing portfolio.
- Sysmex Inostics' RAS-RAF-SEQ assay, a liquid biopsy test, has been approved by the New York State Department of Health for clinical trial use. - The assay targets key mutations in the RAS-RAF and PI3K signaling pathways, relevant in cancers like colorectal, pancreatic, and lung cancers. - RAS-RAF-SEQ utilizes Plasma-Safe-SeqS technology for ultrasensitive detection of low-level genomic mutations, enhancing therapy selection and monitoring. - This approval expands access to Sysmex Inostics' ultrasensitive assays for patients in New York, aiding in assessing novel cancer therapies.
